Skip to content
drillr.ai
Sign up

02005.HK

SSY Group Limited

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK

HKD 2.73
−0.18%
Ask drillr

  • Sep 2, 2026, 09:10 UTC

    SSY Group announced that its Diltiazem Hydrochloride Tablets (30mg) received approval from China's National Medical Products Administration for passing the consistency evaluation of generic drug quality and efficacy, making it the third domestic company to obtain such approval.

    Source:

  • Aug 26, 2026, 04:17 UTC

    SSY Group Limited reported interim results for the six months ended June 2026, with net profit of HK$320 million, up 13% year-on-year, and revenue of HK$2.361 billion, up 9.9%.

    Source:

  • Aug 25, 2026, 08:53 UTC

    SSY Group Limited received regulatory approval from China's National Medical Products Administration to market its Ozagrel Sodium small-volume injections (5ml:40mg and 2.5ml:20mg), classified as Category 3 chemical drugs, deemed to have passed consistency evaluation.

    Source:

  • Aug 20, 2026, 04:09 UTC

    SSY Group Limited received a drug production registration certificate from China's National Medical Products Administration for its Vitamin K1 injection (1ml:10mg), a Class 3 chemical drug deemed equivalent to generic consistency evaluation.

    Source:

  • Aug 6, 2026, 08:42 UTC

    Shijiazhuang No.4 Pharmaceutical Group announced it has obtained drug production registration approvals from China's National Medical Products Administration for 4 products, all deemed to have passed consistency evaluation.

    Source:

  • Jul 23, 2026, 09:46 UTC

    Huahai Pharmaceutical received a drug registration certificate from the National Medical Products Administration for its ferrous succinate tablets, used for the prevention and treatment of iron deficiency anemia.

    Source:

  • Jul 23, 2026, 08:39 UTC

    Shijiazhuang Yiling Pharmaceutical obtained drug production registration approvals from the China National Medical Products Administration for four chemical drugs (Class 4, deemed passing consistency evaluation).

    Source:

  • Jul 21, 2026, 00:47 UTC

    Shijiazhuang Yiling Pharmaceutical's gadobutrol active pharmaceutical ingredient registration was approved by China's National Medical Products Administration.

    Source: